E-cadherin, a key cell adhesion molecule, is fundamentally implicated in maintaining epithelial integrity and tissue architecture. Its loss or functional inactivation disrupts cell-cell adhesion, leading to enhanced cellular dissociation and motility—hallmarks of invasive cancers. While the role of E-cadherin loss has been studied extensively in ductal carcinomas, its specific impact on the tumor microenvironment in invasive lobular breast cancer has remained elusive until now.

The multidisciplinary study led by Djerroudi, Mhaidly, Kieffer, and colleagues employed cutting-edge genomic, proteomic, and imaging technologies to dissect how E-cadherin inactivation transforms the tumor landscape. Their integrative analyses revealed that beyond simply facilitating tumor cell invasion, E-cadherin loss orchestrates a complex reprogramming of the surrounding stromal and immune cells, establishing a tumor microenvironment uniquely conducive to ILC progression.

One of the key findings elucidated how the absence of functional E-cadherin alters signaling pathways that govern extracellular matrix (ECM) composition. The researchers observed a pronounced remodeling of the ECM, characterized by enhanced deposition of collagen fibers and upregulation of matrix metalloproteinases (MMPs). This ECM restructuring not only provides a physical scaffold for tumor dissemination but also modulates mechanotransduction pathways, influencing cancer cell behavior through biomechanical cues.

Concomitantly, E-cadherin inactivation was found to affect the immune milieu profoundly. Single-cell RNA sequencing revealed shifts in immune cell populations, with a notable increase in immunosuppressive macrophages and myeloid-derived suppressor cells (MDSCs), alongside a reduction in cytotoxic T lymphocytes. These immune alterations create a permissive environment for tumor growth by dampening anti-tumor immune responses, thereby enabling immune evasion.

Moreover, the study highlighted that the loss of E-cadherin drives changes in cancer-associated fibroblasts (CAFs). These fibroblasts adopt a more activated phenotype with elevated secretion of pro-inflammatory cytokines and growth factors, contributing to tumor progression and resistance to therapy. The reciprocal crosstalk between tumor cells deficient in E-cadherin and activated CAFs forms a vicious cycle that exacerbates malignant phenotypes.

Significantly, the researchers demonstrated that targeting the downstream effectors of E-cadherin loss could reprogram the tumor microenvironment toward a less aggressive state. Employing pharmacologic inhibitors that interfere with ECM remodeling enzymes and immunosuppressive signaling pathways, they successfully attenuated tumor growth and enhanced the efficacy of immune checkpoint blockade in preclinical ILC models.

These findings underscore the critical interdependence between genetic alterations within cancer cells and the extrinsic tumor microenvironment. They suggest that therapeutic interventions solely aiming at tumor-intrinsic factors may be insufficient for ILC, advocating for combination therapies that concurrently target the microenvironmental components sculpted by E-cadherin inactivation.

At the mechanistic level, the team unraveled that loss of E-cadherin activates a network of transcriptional regulators, including the EMT (epithelial-to-mesenchymal transition)-associated transcription factors such as Snail and Twist. These factors not only suppress epithelial markers but also induce mesenchymal traits that enhance invasiveness and metastatic potential. The interplay between EMT induction and microenvironment remodeling represents a fundamental axis of ILC pathobiology.

From a clinical perspective, these insights provide biomarkers predictive of disease progression and response to treatment. For instance, elevated expression of ECM components and immunoregulatory cytokines associated with E-cadherin loss could serve as stratification tools for personalized therapy. Patients exhibiting this signature might benefit from novel agents that target both the tumor and its microenvironment.

In the broader context of cancer biology, this research exemplifies the paradigm shift toward the holistic understanding of tumors as dynamic ecosystems. It reaffirms that alterations in cellular adhesion molecules reverberate beyond cell-autonomous effects, inducing systemic changes that shape the tumor’s architecture, immune landscape, and therapeutic vulnerabilities.

The integration of multi-omics approaches combined with spatial transcriptomics and in vivo modeling was instrumental in deriving these comprehensive insights. By resolving spatial heterogeneity and intercellular interactions, the researchers were able to map the evolving tumor microenvironment with unprecedented resolution, setting a new standard for future oncological studies.

This landmark study also prompts reconsideration of current therapeutic regimens for ILC, which have largely mirrored those developed for invasive ductal carcinomas. The unique microenvironmental alterations driven by E-cadherin loss necessitate tailored treatment paradigms that address not only tumor cell-intrinsic features but also the supportive niche that nurtures malignancy.

Furthermore, the discovery that E-cadherin inactivation mediates immune suppression suggests potential synergies between ECM-targeting drugs and immunotherapies, such as checkpoint inhibitors. To realize these clinical benefits, however, extensive translational research and well-designed clinical trials will be essential to validate efficacy and safety in human patients.

In conclusion, the elucidation of E-cadherin’s role in sculpting the tumor microenvironment in invasive lobular breast cancer constitutes a seminal advance with profound implications for cancer biology and therapy. By bridging molecular alterations with microenvironmental dynamics, this study charts a transformative path toward precision oncology for a cancer subtype that has remained therapeutically challenging.

As this research garners attention worldwide, it is poised to ignite further investigations into the interplay between adhesion molecules and tumor ecosystems across various cancer types. The promise of harnessing tumor microenvironment vulnerabilities heralds a new era of innovation, with the ultimate goal of improving outcomes for patients afflicted with invasive lobular breast cancer and beyond.

Subject of Research: The impact of E-cadherin inactivation on tumor microenvironment remodeling in invasive lobular breast cancer.

Article Title: E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

Article References:
Djerroudi, L., Mhaidly, R., Kieffer, Y. et al. E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72844-4

Image Credits: AI Generated

Triple-negative breast cancer accounts for approximately 20% of breast cancer cases worldwide. Its hallmark is the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). This receptor-negative status precludes the use of hormonal or HER2-targeted treatments, severely limiting therapeutic options. Clinically, TNBC disproportionately affects younger women, exhibits rapid metastatic potential, and is burdened by a high rate of early recurrence and mortality. These aggressive characteristics have positioned TNBC as a critical challenge in oncology.

Given the lack of conventional molecular targets in TNBC, research efforts have expanded beyond the malignant cells to encompass their surrounding environment. The tumour microenvironment comprises a dynamic consortium of connective tissue, immune cells, fibroblasts, extracellular matrix components, and vasculature. This environment can paradoxically either impede or foster tumorigenesis, suggesting that its molecular interplay may hold keys to combating the disease.

In an innovative study published in Current Drug Therapy, a multidisciplinary team at the HSE Faculty of Biology and Biotechnology dissected the gene expression profiles of both TNBC tumour cells and their microenvironment components. By correlating these molecular data with extensive patient clinical records, they identified critical regulatory pathways influencing tumour aggressiveness and patient outcomes. Central to their discovery is the insulin-like growth factor 2 (IGF2), a well-known signalling protein implicated in tissue growth and repair, but hijacked in cancer to fuel unregulated proliferation.

Contrary to conventional assumptions that the tumour cells produce the essential growth-supporting factors, this study found that fibroblasts—connective tissue cells resident within the tumour microenvironment—are the predominant source of IGF2 in TNBC. These fibroblasts, normally maintaining tissue architecture and homeostasis, seem to switch roles under the pathological state, becoming facilitators of cancer progression by secreting IGF2, effectively “fueling the fire” of tumour expansion.

Adjacent to this growth-promoting mechanism, the tumour possesses an intrinsic regulatory system aimed at tempering unchecked development. This restraint is mediated by the insulin-like growth factor binding protein 6 (IGFBP6), a molecular “trap” that binds IGF2, preventing it from excessive activation of tumour cells. Intriguingly, the researchers observed that both tumour and microenvironmental cells produce IGFBP6 as a counterbalance to growth stimuli, suggesting a finely tuned equilibrium under normal conditions.

The study’s clinical analysis revealed a troubling link between diminished IGFBP6 expression and heightened infiltration of macrophages within tumours. Macrophages, pivotal immune cells tasked with host defense, can undergo functional reprogramming in cancer to adopt tumor-supportive roles. This reprogramming fosters a pro-tumoral milieu, promoting angiogenesis, matrix remodeling, and immune suppression, factors collectively contributing to accelerated disease recurrence and poor prognosis in affected patients.

These findings carry immediate translational significance. Measuring IGFBP6 levels in tumour biopsies could serve as a prognostic biomarker, enabling clinicians to stratify patients by recurrence risk more accurately. High-risk individuals with low IGFBP6 expression and macrophage-enriched tumours might benefit from intensified surveillance and tailored therapeutic regimens, potentially improving survival outcomes.

Looking forward, the elucidation of this tumour microenvironment axis opens exciting prospects for the development of novel treatments. Current chemotherapeutic strategies targeting rapidly dividing cancer cells often fall short against TNBC’s resilience. Redirecting therapeutic focus to the supportive fibroblasts and immune components within the microenvironment offers a promising paradigm shift. For instance, elevating IGFBP6 levels pharmacologically or inhibiting IGF2 production in fibroblasts could undermine the tumour’s growth advantage, effectively “starving” cancer cells of their supportive niche.

Maxim Shkurnikov, leading the research at HSE’s Laboratory for Research on Molecular Mechanisms of Longevity, emphasizes this strategic reorientation: “Conventional chemotherapy primarily targets rapidly dividing cells, and in triple-negative breast cancer this is often insufficient. We propose shifting the focus to the tumour microenvironment and targeting the cells that support tumour growth. By modulating IGFBP6 and IGF2 dynamics, we hope to develop therapies that significantly reduce the risk of rapid recurrence.”

This research underscores the critical importance of the tumour microenvironment in dictating cancer progression and recurrence, particularly in TNBC, where options remain limited. It aligns with a growing body of evidence suggesting that addressing not only the malignant cells but also the surrounding stromal and immune components is essential for durable therapeutic success.

Moreover, this discovery may have implications beyond TNBC, offering insights into other malignancies where the IGF axis and immune microenvironment interplay governs tumour behavior. The identification of biomarkers like IGFBP6 and the delineation of fibroblast-derived IGF2 in cancer progression herald a new wave of personalized oncology approaches grounded in microenvironmental biology.

In summary, the HSE University study marks a significant advance in cancer biology, highlighting that the aggressive nature of triple-negative breast cancer is not solely an intrinsic feature of tumour cells but critically influenced by their microenvironment. By targeting these auxiliary cells and their molecular signals, there lies an opportunity to outmaneuver this formidable disease and improve outcomes for patients currently facing limited options.

Subject of Research: Molecular mechanisms and tumour microenvironment in triple-negative breast cancer

Article Title: IGFBP6 Expression Correlates with Macrophage Presence in Triple-Negative Breast Cancer Tumors

News Publication Date: 2 January 2026

Web References:
https://doi.org/10.2174/0115748855416908251120055038

References:
HSE University research team, Current Drug Therapy, 2026

Keywords:
Triple-negative breast cancer, tumour microenvironment, IGF2, IGFBP6, fibroblasts, macrophages, cancer recurrence, molecular oncology, tumour progression, targeted therapy, immune cells, cancer biomarkers